Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ: KNSA · IEX Real-Time Price · USD
26.12
+0.21 (0.81%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Kiniksa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 338.93 | 270.26 | 220.18 | 38.54 | - | - | Upgrade
|
| Revenue Growth (YoY) | 20.69% | 22.74% | 471.24% | - | - | - | Upgrade
|
| Cost of Revenue | 126.64 | 89.93 | 46.97 | 9.94 | - | - | Upgrade
|
| Gross Profit | 212.29 | 180.33 | 173.21 | 28.61 | - | - | Upgrade
|
| Selling, General & Admin | 152.28 | 129.43 | 97.95 | 85.95 | 45.32 | 34.96 | Upgrade
|
| Research & Development | 87.51 | 76.1 | 65.49 | 99.3 | 112.04 | 135 | Upgrade
|
| Operating Expenses | 239.79 | 205.52 | 163.44 | 185.25 | 157.36 | 169.96 | Upgrade
|
| Operating Income | -27.51 | -25.2 | 9.77 | -156.64 | -157.36 | -169.96 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 6.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.48 | 8.54 | 1.25 | 0.1 | 1.13 | - | Upgrade
|
| Pretax Income | -18.02 | -16.65 | 11.03 | -156.54 | -156.23 | -163.91 | Upgrade
|
| Income Tax Expense | -7.79 | -30.74 | -172.34 | 1.39 | 5.15 | -2.05 | Upgrade
|
| Net Income | -10.23 | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 | Upgrade
|
| Net Income to Common | -10.23 | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 | Upgrade
|
| Net Income Growth | - | -92.32% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 71 | 70 | 69 | 69 | 62 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 72 | 70 | 69 | 62 | 54 | Upgrade
|
| Shares Change (YoY) | -1.36% | 2.13% | 2.69% | 10.89% | 14.42% | 82.92% | Upgrade
|
| EPS (Basic) | -0.15 | 0.20 | 2.64 | -2.30 | -2.61 | -2.99 | Upgrade
|
| EPS (Diluted) | -0.15 | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 | Upgrade
|
| EPS Growth | - | -92.31% | - | - | - | - | Upgrade
|
| Free Cash Flow | - | 13.17 | 5.7 | -126.71 | -136.82 | -161.57 | Upgrade
|
| Free Cash Flow Per Share | - | 0.18 | 0.08 | -1.85 | -2.21 | -2.99 | Upgrade
|
| Gross Margin | 62.63% | 66.72% | 78.67% | 74.22% | - | - | Upgrade
|
| Operating Margin | -8.12% | -9.32% | 4.44% | -406.38% | - | - | Upgrade
|
| Profit Margin | -3.02% | 5.21% | 83.28% | - | - | - | Upgrade
|
| Free Cash Flow Margin | - | 4.87% | 2.59% | -328.75% | - | - | Upgrade
|
| EBITDA | -25.43 | -22.86 | 12.18 | -154.28 | -154.96 | -167.9 | Upgrade
|
| EBITDA Margin | -7.50% | -8.46% | 5.53% | - | - | - | Upgrade
|
| D&A For EBITDA | 2.08 | 2.34 | 2.4 | 2.36 | 2.41 | 2.07 | Upgrade
|
| EBIT | -27.51 | -25.2 | 9.77 | -156.64 | -157.36 | -169.96 | Upgrade
|
| EBIT Margin | -8.12% | -9.32% | 4.44% | - | - | - | Upgrade
|
| Revenue as Reported | 338.93 | 270.26 | 220.18 | 38.54 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template.